CAF-EVs Carry LncRNA MAPKAPK5-AS1 into Hepatocellular Carcinoma Cells and Promote Malignant Cell Proliferation

Overview

Journal Commun Biol

Specialty Biology

Date 2024 Dec 31

PMID 39739005

Authors

Lin Sheng

Junmei Lin

Yili Zhang

Yanping Chen

Xuxing Ye

Xiaobo Wang

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is an aggressive malignancy with poor prognosis. LncRNA MAPKAPK5-AS1 is a potential oncogene and contributes to HCC cell malignant proliferation. This study explores the role of MAPKAPK5-AS1 carried by carcinoma-associated fibroblasts-derived extracellular vesicles (CAF-EVs) in HCC cell proliferation. Our findings reveal that CAF-EVs promotes HCC cell proliferation by delivering MAPKAPK5-AS1, which binds to and inhibits SMURF2 and stabilizes TCF12. SMURF2 leads to TCF12 ubiquitination and degradation. TCF12 upregulates FOXH1 expression. In animal model, CAF-EVs enhances tumor growth by stabilizing TCF12 via MAPKAPK5-AS1 and activating FOXH1 transcription. In conclusion, CAF-EVs carrying MAPKAPK5-AS1 stabilizes TCF12 expression by competitively inhibiting SMURF2, thus promoting TCF12-mediated FOXH1 transcription and driving HCC cell proliferation. Our findings may offer insights for HCC treatment and suggest potential targets for future treatments, opening avenues for HCC therapies.

References

Chaudhary K, Kinslow C, Cheng H, Silva J, Yu J, Wang T . Smurf2 inhibition enhances chemotherapy and radiation sensitivity in non-small-cell lung cancer. Sci Rep. 2022; 12(1):10140. PMC: 9203496. DOI: 10.1038/s41598-022-14448-8. View

Forner A, Reig M, Bruix J . Hepatocellular carcinoma. Lancet. 2018; 391(10127):1301-1314. DOI: 10.1016/S0140-6736(18)30010-2. View

Lv E, Sheng J, Yu C, Rao D, Huang W . Long noncoding RNA MAPKAPK5-AS1 promotes metastasis through regulation miR-376b-5p/ECT2 axis in hepatocellular carcinoma. Dig Liver Dis. 2022; 55(7):945-954. DOI: 10.1016/j.dld.2022.11.024. View

Yang J, Zhang L, Jiang Z, Ge C, Zhao F, Jiang J . TCF12 promotes the tumorigenesis and metastasis of hepatocellular carcinoma via upregulation of CXCR4 expression. Theranostics. 2019; 9(20):5810-5827. PMC: 6735379. DOI: 10.7150/thno.34973. View

Mas-Ponte D, Carlevaro-Fita J, Palumbo E, Hermoso Pulido T, Guigo R, Johnson R . LncATLAS database for subcellular localization of long noncoding RNAs. RNA. 2017; 23(7):1080-1087. PMC: 5473142. DOI: 10.1261/rna.060814.117. View

Tao L, Li D, Mu S, Tian G, Yan G . LncRNA MAPKAPK5_AS1 facilitates cell proliferation in hepatitis B virus -related hepatocellular carcinoma. Lab Invest. 2022; 102(5):494-504. DOI: 10.1038/s41374-022-00731-9. View

Dong Q, Long X, Cheng J, Wang W, Tian Q, Di W . LncRNA GAS5 suppresses ovarian cancer progression by targeting the miR-96-5p/PTEN axis. Ann Transl Med. 2022; 9(24):1770. PMC: 8756204. DOI: 10.21037/atm-21-6134. View

Xu J, Yang B, Wang L, Zhu Y, Zhu X, Xia Z . LncRNA BBOX1-AS1 upregulates HOXC6 expression through miR-361-3p and HuR to drive cervical cancer progression. Cell Prolif. 2020; 53(7):e12823. PMC: 7377938. DOI: 10.1111/cpr.12823. View

Lin Z, Huang W, He Q, Li D, Wang Z, Feng Y . FOXC1 promotes HCC proliferation and metastasis by Upregulating DNMT3B to induce DNA Hypermethylation of CTH promoter. J Exp Clin Cancer Res. 2021; 40(1):50. PMC: 7852227. DOI: 10.1186/s13046-021-01829-6. View

10.

Afaloniati H, Poutahidis T, Giakoustidis A, Gargavanis A, Giakoustidis D, Angelopoulou K . Romidepsin hepatocellular carcinoma suppression in mice is associated with deregulated gene expression of bone morphogenetic protein and Notch signaling pathway components. Mol Biol Rep. 2021; 48(1):551-562. DOI: 10.1007/s11033-020-06089-9. View

11.

Muppirala U, Honavar V, Dobbs D . Predicting RNA-protein interactions using only sequence information. BMC Bioinformatics. 2011; 12:489. PMC: 3322362. DOI: 10.1186/1471-2105-12-489. View

12.

Yugawa K, Yoshizumi T, Mano Y, Itoh S, Harada N, Ikegami T . Cancer-associated fibroblasts promote hepatocellular carcinoma progression through downregulation of exosomal miR-150-3p. Eur J Surg Oncol. 2020; 47(2):384-393. DOI: 10.1016/j.ejso.2020.08.002. View

13.

Ying F, Chan M, Lee T . Cancer-Associated Fibroblasts in Hepatocellular Carcinoma and Cholangiocarcinoma. Cell Mol Gastroenterol Hepatol. 2023; 15(4):985-999. PMC: 10040968. DOI: 10.1016/j.jcmgh.2023.01.006. View

14.

Wang Z, Gao P, Sun W, Ur Rehman A, Jiang J, Xu S . Long noncoding RNA MyD88 functions as a promising diagnostic biomarker in hepatocellular carcinoma. Front Endocrinol (Lausanne). 2023; 14:938102. PMC: 9922760. DOI: 10.3389/fendo.2023.938102. View

15.

Huang A, Yang X, Chung W, Dennison A, Zhou J . Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020; 5(1):146. PMC: 7419547. DOI: 10.1038/s41392-020-00264-x. View

16.

Yang J, Xu Q, Wang Z, Lu X, Pan L, Wu J . Integrated Analysis of an lncRNA-Associated ceRNA Network Reveals Potential Biomarkers for Hepatocellular Carcinoma. J Comput Biol. 2020; 28(3):330-344. DOI: 10.1089/cmb.2019.0250. View

17.

Zhang W, Zhang J, Wu X, Yan T, Lv W . miR-15b promotes epithelial-mesenchymal transition by inhibiting SMURF2 in pancreatic cancer. Int J Oncol. 2015; 47(3):1043-53. DOI: 10.3892/ijo.2015.3076. View

18.

Kim C, Lee H, Gupta N, Ramachandran S, Kaushik I, Srivastava S . Role of Forkhead Box Class O proteins in cancer progression and metastasis. Semin Cancer Biol. 2017; 50:142-151. PMC: 5794649. DOI: 10.1016/j.semcancer.2017.07.007. View

19.

Zulaziz N, Chai S, Lim K . The origins, roles and therapies of cancer associated fibroblast in liver cancer. Front Oncol. 2023; 13:1151373. PMC: 10076538. DOI: 10.3389/fonc.2023.1151373. View

20.

Han M, Guo Y, Li Y, Zeng Q, Zhu W, Jiang J . SMURF2 facilitates ubiquitin-mediated degradation of ID2 to attenuate lung cancer cell proliferation. Int J Biol Sci. 2023; 19(11):3324-3340. PMC: 10367561. DOI: 10.7150/ijbs.80979. View